Jupiter Neurosciences Begins Enrollment in Phase 2a RESET Trial for Parkinson's Disease

With no approved disease-modifying therapy for Parkinson's disease on the market, Jupiter Neurosciences has opened enrollment in its Phase 2a RESET trial (NCT07592767), testing JOTROL™, an investigational trans-resveratrol micellar formulation, in patients with PD. For clinical operations and regulatory leads tracking CNS pipeline assets, the trial's IND clearance in November 2025 and the micellar delivery platform's bioavailability profile are the details that warrant close attention.

JOTROL™'s formulation approach is central to the program's scientific rationale. Phase 1 data from 24 healthy volunteers showed approximately 9-fold higher plasma bioavailability versus conventional resveratrol (Cmax 455 ng/mL vs. 85 ng/mL), a result the company used to support its IND submission. Preclinical work in an established PD model demonstrated statistically significant neuroprotective effects on rotarod performance and grip strength, providing the mechanistic basis for advancing to Phase 2a evaluation.

The RESET study is a multi-center, randomized, double-blind, placebo-controlled design. Georgetown University Medical Center's Charbel Moussa, MBBS, PhD, serves as Coordinating Principal Investigator, citing JOTROL™'s mechanistic profile against oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation as the basis for its differentiation from symptomatic agents currently in use. First patient dosing is expected in the near term following enrollment initiation.

From a manufacturing and quality standpoint, micellar drug delivery systems present distinct process validation considerations: particle size distribution, encapsulation efficiency, and stability under GMP conditions all require tighter specification controls than conventional oral solid dosage forms. Clinical-stage companies advancing novel delivery platforms through 21 CFR Part 211 and ICH Q10 quality system frameworks face heightened scrutiny on these parameters during Phase 2 and beyond, particularly as scale-up planning begins in parallel with efficacy data generation.

Parkinson's disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new diagnoses annually and an estimated annual U.S. economic burden of $82.2 billion. The global PD treatment market, valued at $5.65 billion in 2024, is projected to reach $7.58 billion by 2030 at a CAGR of approximately 5.0%, entirely on the strength of symptomatic therapies given the absence of any approved disease-modifying option.

The measurable checkpoint ahead is the generation of Phase 2a efficacy and safety data, which will determine whether JOTROL™'s bioavailability advantage in healthy volunteers translates to clinically meaningful outcomes in a PD patient population.

Source: Jupiter Neurosciences, Inc. via GlobeNewswire, May 27, 2026.